Abstract
| Original language | English |
|---|---|
| Article number | e0171611 |
| Journal | PLoS One |
| Volume | 12 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2017 |
Fingerprint
Cite this
Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. / Gianotti, N; Cozzi-Lepri, A; Antinori, A; Castagna, A; De Luca, A; Celesia, BM; Galli, M; Mussini, C; Pinnetti, C; Spagnuolo, V; D'Arminio Monforte, A; Ceccherini-Silberstein, F; Andreoni, M; Study, on behalf of Icona Foundation; Cohorts, mono-PI/r database Study.
In: PLoS One, Vol. 12, No. 2, e0171611, 2017.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients
AU - Gianotti, N
AU - Cozzi-Lepri, A
AU - Antinori, A
AU - Castagna, A
AU - De Luca, A
AU - Celesia, BM
AU - Galli, M
AU - Mussini, C
AU - Pinnetti, C
AU - Spagnuolo, V
AU - D'Arminio Monforte, A
AU - Ceccherini-Silberstein, F
AU - Andreoni, M
AU - Study, on behalf of Icona Foundation
AU - Cohorts, mono-PI/r database Study
PY - 2017
Y1 - 2017
N2 - Objective: The primary objective of this study was to estimate the incidence of treatment failure (TF) to protease inhibitor monotherapies (PI/r-MT) with lopinavir/ritonavir (LPV/r) or darunavir/ritonavir (DRV/r). Design: A multicenter cohort of HIV-infected patients with viral load (VL) ≤50 copies/mL, who underwent a switch from any triple combination therapy to PI/r-MT with either LPV/r or DRV/r. Methods: VL was assessed in each center according to local procedures. Residual viremia was defined by any HIV-RNA value detectable below 50 copies/mL by a Real-Time PCR method. Standard survival analysis was used to estimate the rate of TF (defined by virological failure or interruption of monotherapy or reintroduction of combination therapy). A multivariable Cox regression analysis with automatic stepwise procedures was used to identify factors independently associated with TF among nadir and baseline CD4+ counts, residual viremia, time spent with 100 cells/μL) and residual viremia (aHR = 1.48 [95% CI: 1.01-2.17] vs. undetectable VL) were independently associated to TF. Conclusions: Residual viremia and nadir CD4+ counts
AB - Objective: The primary objective of this study was to estimate the incidence of treatment failure (TF) to protease inhibitor monotherapies (PI/r-MT) with lopinavir/ritonavir (LPV/r) or darunavir/ritonavir (DRV/r). Design: A multicenter cohort of HIV-infected patients with viral load (VL) ≤50 copies/mL, who underwent a switch from any triple combination therapy to PI/r-MT with either LPV/r or DRV/r. Methods: VL was assessed in each center according to local procedures. Residual viremia was defined by any HIV-RNA value detectable below 50 copies/mL by a Real-Time PCR method. Standard survival analysis was used to estimate the rate of TF (defined by virological failure or interruption of monotherapy or reintroduction of combination therapy). A multivariable Cox regression analysis with automatic stepwise procedures was used to identify factors independently associated with TF among nadir and baseline CD4+ counts, residual viremia, time spent with 100 cells/μL) and residual viremia (aHR = 1.48 [95% CI: 1.01-2.17] vs. undetectable VL) were independently associated to TF. Conclusions: Residual viremia and nadir CD4+ counts
U2 - 10.1371/journal.pone.0171611
DO - 10.1371/journal.pone.0171611
M3 - Article
VL - 12
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 2
M1 - e0171611
ER -